Investment
Features
FeesSafety
Academy
More
Pluang+

Compare VanEck JP Morgan EM Local Currency Bond ETF (EMLC) vs Heron Therapeutics Inc (HRTX) Price & Performance

VanEck JP Morgan EM Local Currency Bond ETFTrade
Heron Therapeutics IncTrade

Price performance (Past 24H)

Key statistics

VanEck JP Morgan EM Local Currency Bond ETF vs Heron Therapeutics Inc — how do they compare? VanEck JP Morgan EM Local Currency Bond ETF trades at $25.6, while Heron Therapeutics Inc trades at $0.32 (market cap $61.47M). The key difference: VanEck JP Morgan EM Local Currency Bond ETF is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals.

EMLCHRTX
Sector
Fixed IncomeHealth
52-Week High
$26.59$1.49
52-Week Low
$24.83$0.32
Market Cap
$61.47M
Enterprise Value
$168.21M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

VanEck JP Morgan EM Local Currency Bond ETF

EMLC trades at $25.615, showing minimal daily movement with a slight decline of 0.02%. Technical indicators signal a bullish trend with strong moving average support, while oscillators remain neutral. The ETF maintains consistent dividend distributions, with recent payments of $0.13-$0.14 per share. Emerging market debt exposure provides yield advantages over developed markets, though volatility remains a consideration.

The outlook for EMLC appears favorable given the Federal Reserve's accommodative stance and emerging market yield premiums. Key opportunities include attractive fixed income returns compared to Treasury bonds, while risks center on emerging market volatility and inflation concerns. The technical bullish signal supports near-term price stability with potential for gradual appreciation.

Heron Therapeutics Inc

HRTX trades at $0.3507, up 6.21% in the last 24 hours, but technical indicators signal a bearish trend overall. The company reported Q2 2026 revenue of $37.7 million, missing estimates, with a net loss per share of $0.03. Despite a high gross profit margin of 70.07%, negative net income and cash flow from operations highlight financial strain. Analyst consensus remains strongly bullish with 94.74% buy ratings, but recent news includes a Zacks Strong Sell designation on July 15, 2026.

The outlook is mixed: strong analyst support contrasts with weak earnings and bearish technicals. Investment opportunity lies in potential turnaround if revenue growth accelerates, but risks include persistent losses, competitive pressures, and reliance on financing activities. The stock faces significant downside if operational performance does not improve.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About VanEck JP Morgan EM Local Currency Bond ETF

EMLC invests in local currency-denominated government bonds from emerging market countries. It provides exposure to sovereign debt in nations like Brazil, Mexico, and South Africa, allowing investors to gain from high yields and potential local currency appreciation.

Read more on EMLC

About Heron Therapeutics Inc

Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.

Read more on HRTX